Orient Biotech disclosed its 2026 semi-annual report on the evening of August 28. In the first half of the year, it achieved operating revenue of 464 million yuan, up 15.15 percent year on year, but net profit attributable to shareholders of the listed company was negative 222 million yuan, with the loss widening 36.26 percent year on year. The company said the revenue growth mainly came from large-scale sales of infectious disease testing reagents in overseas markets, and the routine testing business showed a stabilizing and recovering trend. Profit pressure mainly stemmed from US dollar exchange losses and the continued release of strategic investment costs. Net cash flow from operating activities was negative 43.1661 million yuan, narrowing sharply by 64.98 percent compared with the same period last year. The company's R&D investment accounted for 17.27 percent of revenue, with 177 new product certifications and 26 authorized patents added, and it is advancing global production capacity layout in the United States, the United Kingdom, Canada and other places. The company is transforming from a single human medical testing business to a dual-track model of human medicine plus animal health, but it cautioned that overall operating results for 2026 may still face loss risks, and the contract dispute involving US Hengjian is still under trial.
Zhejiang Orient Gene Biotech Co LtdNet loss widened 36.26% year on year to -222 million yuan, with profit pressure from FX losses and strategic investment costs.
